(-0.05%) 5 466.66 points
(-0.38%) 38 964 points
(0.28%) 17 768 points
(0.24%) $81.02
(-3.12%) $2.67
(-0.88%) $2 310.20
(-0.32%) $28.78
(1.44%) $1 000.60
(0.30%) $0.936
(0.78%) $10.69
(0.33%) $0.791
(-0.13%) $87.38
Live Chart Being Loaded With Signals
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer\'s and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer\'s disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection...
Stats | |
---|---|
本日の出来高 | 272 208 |
平均出来高 | 0 |
時価総額 | 70.45M |
EPS | $-0.000500 ( Q2 | 2022-08-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.658 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.242 (12.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-06-29 | Monohon Ted | Buy | 250 000 | Stock Option (right to buy) |
2022-06-09 | Bray June | Buy | 54 000 | Stock Option (right to buy) |
2022-06-09 | Bray June | Buy | 0 | |
2022-06-08 | Senner Christopher J. | Buy | 27 000 | Stock Option (right to buy) |
2022-06-08 | Ryan Una S | Buy | 27 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 5 069 399 | Sell: 426 503 |
ボリューム 相関
Cortexyme, Inc. 相関
10 最も正の相関 | |
---|---|
DLUSX | 0.863 |
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cortexyme, Inc. 相関 - 通貨/商品
Cortexyme, Inc. 財務諸表
Annual | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.02 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.02 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.63 |
FY | 2019 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.940 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer\'s and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer\'s disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。